AKT1 and breast carcinoma: In addition, combination strategies for novel PAM pathway inhibitors, including the novel PI3K—mTOR dual inhibitor gedatolisib [82], AKT inhibitor NTQ1062 [83], mTOR inhibitor sapanisertib [84] and vistusertib [85], are also being developed and explored in breast cancer.